ID   A1AT_HUMAN              Reviewed;         418 AA.
AC   P01009; A6PX14; B2RDQ8; Q0PVP5; Q13672; Q53XB8; Q5U0M1; Q7M4R2;
AC   Q86U18; Q86U19; Q96BF9; Q96ES1; Q9P1P0; Q9UCE6; Q9UCM3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   10-MAY-2017, entry version 235.
DE   RecName: Full=Alpha-1-antitrypsin;
DE   AltName: Full=Alpha-1 protease inhibitor;
DE   AltName: Full=Alpha-1-antiproteinase;
DE   AltName: Full=Serpin A1;
DE   Contains:
DE     RecName: Full=Short peptide from AAT;
DE              Short=SPAAT;
DE   Flags: Precursor;
GN   Name=SERPINA1; Synonyms=AAT, PI; ORFNames=PRO0684, PRO2209;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6319097; DOI=10.1089/dna.1983.2.255;
RA   Bollen A., Herzog A., Cravador A., Herion P., Chuchana P.,
RA   van der Straten A., Loriau R., Jacobs P., van Elsen A.;
RT   "Cloning and expression in Escherichia coli of full-length
RT   complementary DNA coding for human alpha 1-antitrypsin.";
RL   DNA 2:255-264(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6093867; DOI=10.1021/bi00316a003;
RA   Long G.L., Chandra T., Woo S.L.C., Davie E.W., Kurachi K.;
RT   "Complete sequence of the cDNA for human alpha 1-antitrypsin and the
RT   gene for the S variant.";
RL   Biochemistry 23:4828-4837(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF MET-382.
RX   PubMed=6387509; DOI=10.1038/312077a0;
RA   Rosenberg S., Barr P.J., Najarian R.C., Hallewell R.A.;
RT   "Synthesis in yeast of a functional oxidation-resistant mutant of
RT   human alpha-antitrypsin.";
RL   Nature 312:77-80(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2985281; DOI=10.1016/S0092-8674(85)80026-X;
RA   Ciliberto G., Dente L., Cortese R.;
RT   "Cell-specific expression of a transfected human alpha 1-antitrypsin
RT   gene.";
RL   Cell 41:531-540(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION OF VARIANT Z.
RX   PubMed=3491072;
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RT   "Identification of a second mutation in the protein-coding sequence of
RT   the Z type alpha 1-antitrypsin gene.";
RL   J. Biol. Chem. 261:15989-15994(1986).
RN   [6]
RP   ERRATUM.
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RL   J. Biol. Chem. 262:10412-10412(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-237 AND
RP   ASP-400.
RC   TISSUE=Liver;
RX   PubMed=17650587;
RA   Shasany A.K., Shukla A.K., Darokar M.P., Saraiya M., Chaturvedi N.,
RA   Tewari L., Khanuja S.P.;
RT   "An alpha-1 antitrypsin genetic variant from India.";
RL   Indian J. Biochem. Biophys. 44:176-178(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-172; ALA-237 AND
RP   LYS-366.
RC   TISSUE=Lymphocyte;
RA   Balduyck M., Porchet N., Aubert J.-P., Zerimech F., Douchain F.,
RA   Verchain S.;
RT   "Characterization of a new variant of alpha1 antitrypsin M Lille
RT   (p.Gly148Trp).";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Ouyang S., Luo L., Wei H., Zhou G.,
RA   Zhou W., Bi J., Zhang Y., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 32 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Fetal liver, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-237.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67; 196-255 AND 387-418.
RX   PubMed=6979715; DOI=10.1038/297655a0;
RA   Leicht M., Long G.L., Chandra T., Kurachi K., Kidd V.J., Mace M. Jr.,
RA   Davie E.W., Woo S.L.C.;
RT   "Sequence homology and structural comparison between the chromosomal
RT   human alpha 1-antitrypsin and chicken ovalbumin genes.";
RL   Nature 297:655-659(1982).
RN   [15]
RP   PRELIMINARY PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RA   Chan S.K.;
RT   "The covalent structure of human alpha1-protease inhibitor.";
RL   Fed. Proc. 41:1016-1016(1982).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RX   PubMed=7045697; DOI=10.1038/298329a0;
RA   Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O., Owen M.C.,
RA   Vaughan L., Boswell D.R.;
RT   "Structure and variation of human alpha 1-antitrypsin.";
RL   Nature 298:329-334(1982).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1), VARIANTS ABERRANT FORM
RP   190-GLY--ARG-198 AND VAL-288, AND FUNCTION.
RC   TISSUE=Blood;
RA   Sinha A.K., Girish G.V.;
RT   "Appearance of an aberrant form of alpha-antitrypsin in the
RT   circulation of chronic cigarette smokers and its effect on the insulin
RT   induced NO synthesis in blood platelets.";
RL   Submitted (AUG-2007) to UniProtKB.
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39, AND FUNCTION.
RC   TISSUE=Ascites;
RX   PubMed=1906855; DOI=10.1111/j.1349-7006.1991.tb01905.x;
RA   Tanaka N., Sekiya S., Takamizawa H., Kato N., Moriyama Y.,
RA   Fujimura S.;
RT   "Characterization of a 54 kDa, alpha 1-antitrypsin-like protein
RT   isolated from ascitic fluid of an endometrial cancer patient.";
RL   Jpn. J. Cancer Res. 82:693-700(1991).
RN   [19]
RP   PROTEIN SEQUENCE OF 30-48 AND 248-257 (ISOFORMS 1/2/3), GLYCOSYLATION
RP   AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES,
RP   CYSTEINE-BINDING, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16622833; DOI=10.1002/pmic.200500751;
RA   Kolarich D., Weber A., Turecek P.L., Schwarz H.P., Altmann F.;
RT   "Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin
RT   and its charge isoforms.";
RL   Proteomics 6:3369-3380(2006).
RN   [20]
RP   PROTEIN SEQUENCE OF 47-66.
RC   TISSUE=Urine;
RX   PubMed=8323530; DOI=10.1006/bbrc.1993.1731;
RA   Umekawa T., Kohri K., Amasaki N., Yamate T., Yoshida K., Yamamoto K.,
RA   Suzuki Y., Sinohara H., Kurita T.;
RT   "Sequencing of a urinary stone protein, identical to alpha-one
RT   antitrypsin, which lacks 22 amino acids.";
RL   Biochem. Biophys. Res. Commun. 193:1049-1053(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 50-63 AND 161-178 (ISOFORMS 1/2/3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-418 (ISOFORM 1).
RX   PubMed=3876243; DOI=10.1016/0014-5793(85)81056-5;
RA   Riley J.H., Bathurst I.C., Edbrooke M.R., Carrell R.W., Craig R.K.;
RT   "Alpha 1-antitrypsin and serum albumin mRNA accumulation in normal,
RT   acute phase and ZZ human liver.";
RL   FEBS Lett. 189:361-366(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 350-418 (ISOFORM 1).
RX   PubMed=7031661; DOI=10.1073/pnas.78.11.6826;
RA   Kurachi K., Chandra T., Friezner Degen S.J., White T.T.,
RA   Marchioro T.L., Woo S.L.C., Davie E.W.;
RT   "Cloning and sequence of cDNA coding for alpha 1-antitrypsin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6826-6830(1981).
RN   [24]
RP   PROTEIN SEQUENCE OF 375-414, IDENTIFICATION OF SPAAT, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=1406456;
RA   Niemann M.A., Narkates A.J., Miller E.J.;
RT   "Isolation and serine protease inhibitory activity of the 44-residue,
RT   C-terminal fragment of alpha 1-antitrypsin from human placenta.";
RL   Matrix 12:233-241(1992).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 387-418 (ISOFORM 1).
RX   PubMed=3873938;
RA   Coutelle C., Speer A., Rogers J., Kalsheker N., Humphries S.,
RA   Williamson R.;
RT   "Construction and partial characterization of a human liver cDNA
RT   library.";
RL   Biomed. Biochim. Acta 44:421-431(1985).
RN   [26]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [32]
RP   GLYCOSYLATION AT ASN-107 AND ASN-271.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   PHOSPHORYLATION AT SER-38.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=6332197; DOI=10.1016/0022-2836(84)90298-5;
RA   Loebermann H., Tokuoka R., Deisenhofer J., Huber R.;
RT   "Human alpha 1-proteinase inhibitor. Crystal structure analysis of two
RT   crystal modifications, molecular model and preliminary analysis of the
RT   implications for function.";
RL   J. Mol. Biol. 177:531-556(1984).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=2785270; DOI=10.1093/protein/2.6.407;
RA   Engh R., Loebermann H., Schneider M., Wiegand G., Huber R.,
RA   Laurell C.-B.;
RT   "The S variant of human alpha 1-antitrypsin, structure and
RT   implications for function and metabolism.";
RL   Protein Eng. 2:407-415(1989).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 25-418.
RX   PubMed=8543039; DOI=10.1016/0014-5793(95)01331-8;
RA   Song H.K., Lee K.N., Kwon K.-S., Yu M.-H., Suh S.W.;
RT   "Crystal structure of an uncleaved alpha 1-antitrypsin reveals the
RT   conformation of its inhibitory reactive loop.";
RL   FEBS Lett. 377:150-154(1995).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=8756325; DOI=10.1038/nsb0896-676;
RA   Elliott P.R., Lomas D.A., Carrell R.W., Abrahams J.P.;
RT   "Inhibitory conformation of the reactive loop of alpha 1-
RT   antitrypsin.";
RL   Nat. Struct. Biol. 3:676-681(1996).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 45-418.
RX   PubMed=8939743; DOI=10.1016/S0969-2126(96)00126-8;
RA   Ryu S.-E., Choi H.-J., Kwon K.-S., Lee K.N., Yu M.-H.;
RT   "The native strains in the hydrophobic core and flexible reactive loop
RT   of a serine protease inhibitor: crystal structure of an uncleaved
RT   alpha1-antitrypsin at 2.7 A.";
RL   Structure 4:1181-1192(1996).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=9466920; DOI=10.1006/jmbi.1997.1458;
RA   Elliott P.R., Abrahams J.P., Lomas D.A.;
RT   "Wild-type alpha 1-antitrypsin is in the canonical inhibitory
RT   conformation.";
RL   J. Mol. Biol. 275:419-425(1998).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 48-418 IN COMPLEX WITH BOVINE
RP   TRYPSIN.
RX   PubMed=11057674; DOI=10.1038/35038119;
RA   Huntington J.A., Read R.J., Carrell R.W.;
RT   "Structure of a serpin-protease complex shows inhibition by
RT   deformation.";
RL   Nature 407:923-926(2000).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 44-418.
RX   PubMed=10716194; DOI=10.1110/ps.9.2.417;
RA   Dunstone M.A., Dai W., Whisstock J.C., Rossjohn J., Pike R.N.,
RA   Feil S.C., Le Bonniec B.F., Parker M.W., Bottomley S.P.;
RT   "Cleaved antitrypsin polymers at atomic resolution.";
RL   Protein Sci. 9:417-420(2000).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10933492; DOI=10.1110/ps.9.7.1274;
RA   Elliott P.R., Pei X.Y., Dafforn T.R., Lomas D.A.;
RT   "Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets
RT   for rational drug design to prevent conformational disease.";
RL   Protein Sci. 9:1274-1281(2000).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-418.
RX   PubMed=11178897; DOI=10.1006/jmbi.2000.4357;
RA   Kim S.-J., Woo J.-R., Seo E.J., Yu M.-H., Ryu S.-E.;
RT   "A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin
RT   shows variability of the reactive center and other loops.";
RL   J. Mol. Biol. 306:109-119(2001).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-418.
RX   PubMed=12244055; DOI=10.1074/jbc.M207682200;
RA   Im H., Woo M.-S., Hwang K.Y., Yu M.-H.;
RT   "Interactions causing the kinetic trap in serpin protein folding.";
RL   J. Biol. Chem. 277:46347-46354(2002).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-418 OF VARIANT PITTSBURGH
RP   ARG-382.
RX   PubMed=12860985; DOI=10.1074/jbc.M305195200;
RA   Dementiev A., Simonovic M., Volz K., Gettins P.G.;
RT   "Canonical inhibitor-like interactions explain reactivity of alpha1-
RT   proteinase inhibitor Pittsburgh and antithrombin with proteinases.";
RL   J. Biol. Chem. 278:37881-37887(2003).
RN   [51]
RP   REVIEW.
RX   PubMed=2669992; DOI=10.1007/BF01115992;
RA   Kalsheker N.;
RT   "Alpha 1-antitrypsin: structure, function and molecular biology of the
RT   gene.";
RL   Biosci. Rep. 9:129-138(1989).
RN   [52]
RP   REVIEW.
RX   PubMed=1859394; DOI=10.1002/bies.950130404;
RA   Wu Y., Foreman R.C.;
RT   "The molecular genetics of alpha 1 antitrypsin deficiency.";
RL   Bioessays 13:163-169(1991).
RN   [53]
RP   CHARACTERIZATION OF VARIANT M2, AND POLYMORPHISM.
RX   PubMed=2901226;
RA   Nukiwa T., Brantly M.L., Ogushi F., Fells G.A., Crystal R.G.;
RT   "Characterization of the gene and protein of the common alpha 1-
RT   antitrypsin normal M2 allele.";
RL   Am. J. Hum. Genet. 43:322-330(1988).
RN   [54]
RP   VARIANT M3 ASP-400.
RX   PubMed=2394452; DOI=10.1007/BF00206766;
RA   Graham A., Hayes K., Weidinger S., Newton C.R., Markham A.F.,
RA   Kalsheker N.A.;
RT   "Characterisation of the alpha-1-antitrypsin M3 gene, a normal
RT   variant.";
RL   Hum. Genet. 85:381-382(1990).
RN   [55]
RP   VARIANT F CYS-247.
RX   PubMed=2035534;
RA   Okayama H., Brantly M., Holmes M., Crystal R.G.;
RT   "Characterization of the molecular basis of the alpha 1-antitrypsin F
RT   allele.";
RL   Am. J. Hum. Genet. 48:1154-1158(1991).
RN   [56]
RP   VARIANT M-HEERLEN LEU-393.
RX   PubMed=2784123; DOI=10.1007/BF00279001;
RA   Hofker M.H., Nukiwa T., van Paassen H.M.B., Nelen M., Kramps J.A.,
RA   Klasen E.C., Frants R.R., Crystal R.G.;
RT   "A Pro-->Leu substitution in codon 369 of the alpha-1-antitrypsin
RT   deficiency variant PI M-Heerlen.";
RL   Hum. Genet. 81:264-268(1989).
RN   [57]
RP   VARIANT M-MALTON PHE-75 DEL.
RX   PubMed=2786335;
RA   Fraizer G.C., Harrold T.R., Hofker M.H., Cox D.W.;
RT   "In-frame single codon deletion in the M-Malton deficiency allele of
RT   alpha 1-antitrypsin.";
RL   Am. J. Hum. Genet. 44:894-902(1989).
RN   [58]
RP   VARIANT M-MINERAL SPRINGS GLU-91.
RX   PubMed=1967187; DOI=10.1128/MCB.10.1.47;
RA   Curiel D.T., Vogelmeier C., Hubbard R.C., Stier L.E., Crystal R.G.;
RT   "Molecular basis of alpha 1-antitrypsin deficiency and emphysema
RT   associated with the alpha 1-antitrypsin M-Mineral springs allele.";
RL   Mol. Cell. Biol. 10:47-56(1990).
RN   [59]
RP   VARIANT M-NICHINAN PHE-75 DEL.
RX   PubMed=2309708;
RA   Matsunaga E., Shiokawa S., Nakamura H., Maruyama T., Tsuda K.,
RA   Fukumaki Y.;
RT   "Molecular analysis of the gene of the alpha 1-antitrypsin deficiency
RT   variant, M-Nichinan.";
RL   Am. J. Hum. Genet. 46:602-612(1990).
RN   [60]
RP   VARIANT M-PROCIDA PRO-65.
RX   PubMed=3262617;
RA   Takahashi H., Nukiwa T., Satoh K., Ogushi F., Brantly M., Fells G.,
RA   Stier L., Courtney M., Crystal R.G.;
RT   "Characterization of the gene and protein of the alpha 1-antitrypsin
RT   'deficiency' allele M-Procida.";
RL   J. Biol. Chem. 263:15528-15534(1988).
RN   [61]
RP   VARIANT P-DUARTE VAL-280.
RX   PubMed=8364590; DOI=10.1002/humu.1380020311;
RA   Hildesheim J., Kinsley G., Bissell M., Pierce J., Brantly M.;
RT   "Genetic diversity from a limited repertoire of mutations on different
RT   common allelic backgrounds: alpha 1-antitrypsin deficiency variant P-
RT   Duarte.";
RL   Hum. Mutat. 2:221-228(1993).
RN   [62]
RP   INVOLVEMENT OF VARIANT PITTSBURGH ARG-382 IN BLEEDING DIATHESIS.
RX   PubMed=6604220; DOI=10.1056/NEJM198309223091203;
RA   Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W.;
RT   "Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin
RT   Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.";
RL   N. Engl. J. Med. 309:694-698(1983).
RN   [63]
RP   INVOLVEMENT IN A1ATD, AND VARIANT S-IIYAMA PHE-77.
RX   PubMed=1905728;
RA   Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., Kira S.;
RT   "Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-
RT   antitrypsin-deficient variant with mutation on a predicted conserved
RT   residue of the serpin backbone.";
RL   J. Biol. Chem. 266:12627-12632(1991).
RN   [64]
RP   VARIANT V-MUNICH ALA-26.
RX   PubMed=2316526;
RA   Holmes M.D., Brantly M.L., Curiel D.T., Weidinger S., Crystal R.G.;
RT   "Characterization of the normal alpha 1-antitrypsin allele V-Munich: a
RT   variant associated with a unique protein isoelectric focusing
RT   pattern.";
RL   Am. J. Hum. Genet. 46:810-816(1990).
RN   [65]
RP   INVOLVEMENT IN A1ATD, AND VARIANT W-BETHESDA THR-360.
RX   PubMed=2390072; DOI=10.1016/0006-291X(90)90493-7;
RA   Holmes M.D., Brantly M.L., Fells G.A., Crystal R.G.;
RT   "Alpha 1-antitrypsin W-Bethesda: molecular basis of an unusual alpha
RT   1-antitrypsin deficiency variant.";
RL   Biochem. Biophys. Res. Commun. 170:1013-1020(1990).
RN   [66]
RP   VARIANT Z-AUGSBURG LYS-366.
RX   PubMed=2339709;
RA   Faber J.-P., Weidinger S., Olek K.;
RT   "Sequence data of the rare deficient alpha 1-antitrypsin variant PI
RT   Zaugsburg.";
RL   Am. J. Hum. Genet. 46:1158-1162(1990).
RN   [67]
RP   INVOLVEMENT IN A1ATD, AND VARIANTS Z-WREXHAM LEU-4 AND Q0-NEWPORT
RP   SER-139.
RX   PubMed=2227940; DOI=10.1007/BF00194233;
RA   Graham A., Kalsheker N.A., Bamforth F.J., Newton C.R., Markham A.F.;
RT   "Molecular characterisation of two alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) Null(Newport) (Gly115-->Ser) and
RT   (Pi) Z Wrexham (Ser-19-->Leu).";
RL   Hum. Genet. 85:537-540(1990).
RN   [68]
RP   VARIANTS P-CARDIFF VAL-280; I CYS-63 AND M-MALTON PHE-75 DEL.
RX   PubMed=2606478; DOI=10.1007/BF00210671;
RA   Graham A., Kalsheker N.A., Newton C.R., Bamforth F.J., Powell S.J.,
RA   Markham A.F.;
RT   "Molecular characterisation of three alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) nullcardiff (Asp256-->Val); PiM-
RT   Malton (Phe51-->deletion) and PiI (Arg39-->Cys).";
RL   Hum. Genet. 84:55-58(1989).
RN   [69]
RP   VARIANT QO-LUDWIGSHAFEN ASN-116.
RX   PubMed=2254451; DOI=10.1172/JCI114919;
RA   Fraizer G.C., Siewertsen M.A., Hofker M.H., Brubacher M.G., Cox D.W.;
RT   "A null deficiency allele of alpha 1-antitrypsin, QO-Ludwigshafen,
RT   with altered tertiary structure.";
RL   J. Clin. Invest. 86:1878-1884(1990).
RN   [70]
RP   VARIANTS.
RX   PubMed=7977369;
RA   Faber J.-P., Poller W., Weidinger S., Kirchgesser M., Schwaab R.,
RA   Bidlingmaier F., Olek K.;
RT   "Identification and DNA sequence analysis of 15 new alpha 1-
RT   antitrypsin variants, including two PI*Q0 alleles and one deficient
RT   PI*M allele.";
RL   Am. J. Hum. Genet. 55:1113-1121(1994).
RN   [71]
RP   VARIANT Z-BRISTOL MET-109.
RX   PubMed=9459000; DOI=10.1017/S0003480097006404;
RA   Lovegrove J.U., Jeremiah S., Gillett G.T., Temple I.K., Povey S.,
RA   Whitehouse D.B.;
RT   "A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI ZBristol)
RT   associated with novel electrophoretic properties.";
RL   Ann. Hum. Genet. 61:385-391(1997).
RN   [72]
RP   VARIANTS Y-BARCELONA VAL-280 AND HIS-415.
RX   PubMed=10651487;
RA   Jardi R., Rodriguez F., Miravitlles M., Vidal R., Cotrina M., Quer J.,
RA   Pascual C., Weidinger S.;
RT   "Identification and molecular characterization of the new alpha-1-
RT   antitrypsin deficient allele PI YBarcelona (Asp256Val and
RT   Pro391His).";
RL   Hum. Mutat. 12:213-213(1998).
RN   [73]
RP   VARIANT SAO TOME HIS-386.
RA   Seixas S., Trovoada M.J., Santos M.T., Rocha J.;
RT   "A novel alpha-1-antitrypsin P362H variant found in a population
RT   sample from Sao Tome e Principe (Gulf of Guinea, West Africa).";
RL   Hum. Mutat. 13:414-414(1999).
RN   [74]
RP   VARIANT BASQUE ARG-305 DEL.
RX   PubMed=10612848;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<121::AID-HUMU37>3.0.CO;2-U;
RA   Seixas S., Garcia O., Amorim A., Rocha J.;
RT   "A novel alpha-1-antitrypsin r281del variant found in a population
RT   sample from the Basque country.";
RL   Hum. Mutat. 15:121-122(2000).
RN   [75]
RP   VARIANTS Z ALA-237 AND LYS-366, VARIANT S VAL-288, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, GLYCOSYLATION, AND INTERACTION WITH CANX
RP   AND PDIA3.
RX   PubMed=23826168; DOI=10.1371/journal.pone.0066889;
RA   Marques P.I., Ferreira Z., Martins M., Figueiredo J., Silva D.I.,
RA   Castro P., Morales-Hojas R., Simoes-Correia J., Seixas S.;
RT   "SERPINA2 is a novel gene with a divergent function from SERPINA1.";
RL   PLoS ONE 8:E66889-E66889(2013).
RN   [76]
RP   VARIANT PITTSBURGH ARG-382, AND CHARACTERIZATION OF VARIANT PITTSBURGH
RP   ARG-382.
RX   PubMed=26797521; DOI=10.1016/j.bbrc.2016.01.069;
RA   Sheffield W.P., Bhakta V.;
RT   "The M358R variant of alpha(1)-proteinase inhibitor inhibits
RT   coagulation factor VIIa.";
RL   Biochem. Biophys. Res. Commun. 470:710-713(2016).
CC   -!- FUNCTION: Inhibitor of serine proteases. Its primary target is
CC       elastase, but it also has a moderate affinity for plasmin and
CC       thrombin. Irreversibly inhibits trypsin, chymotrypsin and
CC       plasminogen activator. The aberrant form inhibits insulin-induced
CC       NO synthesis in platelets, decreases coagulation time and has
CC       proteolytic activity against insulin and plasmin.
CC   -!- FUNCTION: Short peptide from AAT: reversible chymotrypsin
CC       inhibitor. It also inhibits elastase, but not trypsin. Its major
CC       physiological function is the protection of the lower respiratory
CC       tract against proteolytic destruction by human leukocyte elastase
CC       (HLE).
CC   -!- SUBUNIT: The variants S and Z interact with CANX AND PDIA3.
CC       {ECO:0000269|PubMed:11057674}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-986224, EBI-986224;
CC       P00760:- (xeno); NbExp=5; IntAct=EBI-986224, EBI-986385;
CC       P00772:CELA1 (xeno); NbExp=2; IntAct=EBI-986224, EBI-986248;
CC       P71213:espB (xeno); NbExp=3; IntAct=EBI-986224, EBI-2615322;
CC       P43307:SSR1; NbExp=4; IntAct=EBI-986224, EBI-714168;
CC   -!- SUBCELLULAR LOCATION: Secreted. Endoplasmic reticulum. Note=The S
CC       and Z allele are not secreted effectively and accumulate
CC       intracellularly in the endoplasmic reticulum.
CC   -!- SUBCELLULAR LOCATION: Short peptide from AAT: Secreted,
CC       extracellular space, extracellular matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01009-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01009-2; Sequence=VSP_028889;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P01009-3; Sequence=VSP_028890;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in leukocytes and
CC       plasma. {ECO:0000269|PubMed:23826168}.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N-glycosylated. Differential glycosylation produces a number
CC       of isoforms. N-linked glycan at Asn-107 is alternatively di-
CC       antennary, tri-antennary or tetra-antennary. The glycan at Asn-70
CC       is di-antennary with trace amounts of tri-antennary. Glycan at
CC       Asn-271 is exclusively di-antennary. Structure of glycans at Asn-
CC       70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is
CC       Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure
CC       Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc.
CC       Some antennae are fucosylated, which forms a Lewis-X determinant.
CC       {ECO:0000269|PubMed:12754519, ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:15084671, ECO:0000269|PubMed:16263699,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16622833,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:22171320,
CC       ECO:0000269|PubMed:23826168}.
CC   -!- PTM: Proteolytic processing may yield the truncated form that
CC       ranges from Asp-30 to Lys-418.
CC   -!- POLYMORPHISM: The sequence shown is that of the M1V allele which
CC       is the most common form of PI (44 to 49%). Other frequent alleles
CC       are: M1A 20 to 23%; M2 10 to 11%; M3 14 to 19%.
CC       {ECO:0000269|PubMed:2901226}.
CC   -!- DISEASE: Alpha-1-antitrypsin deficiency (A1ATD) [MIM:613490]: A
CC       disorder whose most common manifestation is emphysema, which
CC       becomes evident by the third to fourth decade. A less common
CC       manifestation of the deficiency is liver disease, which occurs in
CC       children and adults, and may result in cirrhosis and liver
CC       failure. Environmental factors, particularly cigarette smoking,
CC       greatly increase the risk of emphysema at an earlier age.
CC       {ECO:0000269|PubMed:1905728, ECO:0000269|PubMed:2227940,
CC       ECO:0000269|PubMed:2390072}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The aberrant form is found in the plasma of chronic
CC       smokers, and persists after smoking is ceased. It can still be
CC       found ten years after smoking has ceased.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD62334.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD62585.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antitrypsin entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha_1-antitrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01396; AAB59375.1; -; mRNA.
DR   EMBL; K02212; AAB59495.1; -; Genomic_DNA.
DR   EMBL; X01683; CAA25838.1; -; mRNA.
DR   EMBL; M11465; AAA51546.1; -; mRNA.
DR   EMBL; J02619; AAA51547.1; -; Genomic_DNA.
DR   EMBL; DQ682455; ABG73380.1; -; mRNA.
DR   EMBL; AM048838; CAJ15161.1; -; Genomic_DNA.
DR   EMBL; AF113676; AAF29581.1; -; mRNA.
DR   EMBL; AF130068; AAG35496.1; -; mRNA.
DR   EMBL; BX161449; CAD61914.1; -; mRNA.
DR   EMBL; BX247968; CAD62306.1; -; mRNA.
DR   EMBL; BX248002; CAD62334.1; ALT_INIT; mRNA.
DR   EMBL; BX248257; CAD62585.1; ALT_INIT; mRNA.
DR   EMBL; AK315637; BAG38005.1; -; mRNA.
DR   EMBL; BT019455; AAV38262.1; -; mRNA.
DR   EMBL; BC011991; AAH11991.1; -; mRNA.
DR   EMBL; BC015642; AAH15642.1; -; mRNA.
DR   EMBL; J00064; AAB59369.1; -; Genomic_DNA.
DR   EMBL; J00066; AAB59370.1; -; Genomic_DNA.
DR   EMBL; J00065; AAB59370.1; JOINED; Genomic_DNA.
DR   EMBL; J00067; AAB59371.1; -; Genomic_DNA.
DR   EMBL; X02920; CAA26677.1; -; mRNA.
DR   EMBL; V00496; CAA23755.1; -; mRNA.
DR   EMBL; M26123; AAA51545.1; -; mRNA.
DR   CCDS; CCDS9925.1; -. [P01009-1]
DR   PIR; A21853; ITHU.
DR   PIR; A61391; A61391.
DR   RefSeq; NP_000286.3; NM_000295.4. [P01009-1]
DR   RefSeq; NP_001002235.1; NM_001002235.2. [P01009-1]
DR   RefSeq; NP_001002236.1; NM_001002236.2. [P01009-1]
DR   RefSeq; NP_001121172.1; NM_001127700.1. [P01009-1]
DR   RefSeq; NP_001121173.1; NM_001127701.1. [P01009-1]
DR   RefSeq; NP_001121174.1; NM_001127702.1. [P01009-1]
DR   RefSeq; NP_001121175.1; NM_001127703.1. [P01009-1]
DR   RefSeq; NP_001121176.1; NM_001127704.1. [P01009-1]
DR   RefSeq; NP_001121177.1; NM_001127705.1. [P01009-1]
DR   RefSeq; NP_001121178.1; NM_001127706.1. [P01009-1]
DR   RefSeq; NP_001121179.1; NM_001127707.1. [P01009-1]
DR   RefSeq; XP_016876859.1; XM_017021370.1. [P01009-1]
DR   UniGene; Hs.525557; -.
DR   PDB; 1ATU; X-ray; 2.70 A; A=45-418.
DR   PDB; 1D5S; X-ray; 3.00 A; A=44-377, B=378-418.
DR   PDB; 1EZX; X-ray; 2.60 A; A=48-382, B=383-418.
DR   PDB; 1HP7; X-ray; 2.10 A; A=25-418.
DR   PDB; 1IZ2; X-ray; 2.20 A; A=25-418.
DR   PDB; 1KCT; X-ray; 3.46 A; A=25-418.
DR   PDB; 1OO8; X-ray; 2.65 A; A=26-418.
DR   PDB; 1OPH; X-ray; 2.30 A; A=26-418.
DR   PDB; 1PSI; X-ray; 2.92 A; A=26-418.
DR   PDB; 1QLP; X-ray; 2.00 A; A=26-418.
DR   PDB; 1QMB; X-ray; 2.60 A; A=49-376, B=377-418.
DR   PDB; 2D26; X-ray; 3.30 A; A=25-382, B=383-418.
DR   PDB; 2QUG; X-ray; 2.00 A; A=25-418.
DR   PDB; 3CWL; X-ray; 2.44 A; A=25-418.
DR   PDB; 3CWM; X-ray; 2.51 A; A=25-418.
DR   PDB; 3DRM; X-ray; 2.20 A; A=26-418.
DR   PDB; 3DRU; X-ray; 3.20 A; A/B/C=26-418.
DR   PDB; 3NDD; X-ray; 1.50 A; A=46-382, B=383-418.
DR   PDB; 3NDF; X-ray; 2.70 A; A=46-382, B=383-418.
DR   PDB; 3NE4; X-ray; 1.81 A; A=48-418.
DR   PDB; 3T1P; X-ray; 3.90 A; A=48-418.
DR   PDB; 4PYW; X-ray; 1.91 A; A=26-418.
DR   PDB; 5IO1; X-ray; 3.34 A; A/B=29-418.
DR   PDB; 7API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDB; 8API; X-ray; 3.10 A; A=36-382, B=383-418.
DR   PDB; 9API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDBsum; 1ATU; -.
DR   PDBsum; 1D5S; -.
DR   PDBsum; 1EZX; -.
DR   PDBsum; 1HP7; -.
DR   PDBsum; 1IZ2; -.
DR   PDBsum; 1KCT; -.
DR   PDBsum; 1OO8; -.
DR   PDBsum; 1OPH; -.
DR   PDBsum; 1PSI; -.
DR   PDBsum; 1QLP; -.
DR   PDBsum; 1QMB; -.
DR   PDBsum; 2D26; -.
DR   PDBsum; 2QUG; -.
DR   PDBsum; 3CWL; -.
DR   PDBsum; 3CWM; -.
DR   PDBsum; 3DRM; -.
DR   PDBsum; 3DRU; -.
DR   PDBsum; 3NDD; -.
DR   PDBsum; 3NDF; -.
DR   PDBsum; 3NE4; -.
DR   PDBsum; 3T1P; -.
DR   PDBsum; 4PYW; -.
DR   PDBsum; 5IO1; -.
DR   PDBsum; 7API; -.
DR   PDBsum; 8API; -.
DR   PDBsum; 9API; -.
DR   ProteinModelPortal; P01009; -.
DR   SMR; P01009; -.
DR   BioGrid; 111283; 37.
DR   DIP; DIP-35493N; -.
DR   IntAct; P01009; 20.
DR   MINT; MINT-365327; -.
DR   STRING; 9606.ENSP00000348068; -.
DR   DrugBank; DB03345; Beta-Mercaptoethanol.
DR   DrugBank; DB05481; Recombinant alpha 1-antitrypsin.
DR   MEROPS; I04.001; -.
DR   iPTMnet; P01009; -.
DR   PhosphoSitePlus; P01009; -.
DR   UniCarbKB; P01009; -.
DR   BioMuta; SERPINA1; -.
DR   DMDM; 1703025; -.
DR   DOSAC-COBS-2DPAGE; P01009; -.
DR   OGP; P01009; -.
DR   REPRODUCTION-2DPAGE; IPI00553177; -.
DR   REPRODUCTION-2DPAGE; P01009; -.
DR   SWISS-2DPAGE; P01009; -.
DR   UCD-2DPAGE; P01009; -.
DR   EPD; P01009; -.
DR   MaxQB; P01009; -.
DR   PaxDb; P01009; -.
DR   PeptideAtlas; P01009; -.
DR   PRIDE; P01009; -.
DR   DNASU; 5265; -.
DR   Ensembl; ENST00000355814; ENSP00000348068; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393087; ENSP00000376802; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393088; ENSP00000376803; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000402629; ENSP00000386094; ENSG00000197249. [P01009-2]
DR   Ensembl; ENST00000404814; ENSP00000385960; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000437397; ENSP00000408474; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000440909; ENSP00000390299; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000448921; ENSP00000416066; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000449399; ENSP00000416354; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000489769; ENSP00000451525; ENSG00000197249. [P01009-3]
DR   Ensembl; ENST00000636712; ENSP00000490054; ENSG00000197249. [P01009-1]
DR   GeneID; 5265; -.
DR   KEGG; hsa:5265; -.
DR   UCSC; uc001ycx.5; human. [P01009-1]
DR   CTD; 5265; -.
DR   DisGeNET; 5265; -.
DR   GeneCards; SERPINA1; -.
DR   GeneReviews; SERPINA1; -.
DR   HGNC; HGNC:8941; SERPINA1.
DR   HPA; CAB013211; -.
DR   HPA; CAB016648; -.
DR   HPA; CAB073396; -.
DR   HPA; HPA000927; -.
DR   HPA; HPA001292; -.
DR   MalaCards; SERPINA1; -.
DR   MIM; 107400; gene.
DR   MIM; 613490; phenotype.
DR   neXtProt; NX_P01009; -.
DR   OpenTargets; ENSG00000197249; -.
DR   Orphanet; 60; Alpha-1-antitrypsin deficiency.
DR   Orphanet; 178396; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation.
DR   PharmGKB; PA35509; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00760000118839; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01009; -.
DR   KO; K03984; -.
DR   OMA; NITEMSE; -.
DR   OrthoDB; EOG091G0ION; -.
DR   PhylomeDB; P01009; -.
DR   TreeFam; TF343201; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-5694530; Cargo concentration in the ER.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P01009; -.
DR   ChiTaRS; SERPINA1; human.
DR   EvolutionaryTrace; P01009; -.
DR   GeneWiki; Alpha_1-antitrypsin; -.
DR   GenomeRNAi; 5265; -.
DR   PMAP-CutDB; P01009; -.
DR   PRO; PR:P01009; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000197249; -.
DR   ExpressionAtlas; P01009; baseline and differential.
DR   Genevisible; P01009; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:GOC.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:MGI.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; IEA:UniProtKB-KW.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0006888; P:ER to Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Blood coagulation;
KW   Complete proteome; Direct protein sequencing; Endoplasmic reticulum;
KW   Extracellular matrix; Glycoprotein; Hemostasis; Phosphoprotein;
KW   Polymorphism; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:1906855}.
FT   CHAIN        25    418       Alpha-1-antitrypsin.
FT                                {ECO:0000269|PubMed:6093867}.
FT                                /FTId=PRO_0000032377.
FT   PEPTIDE     375    418       Short peptide from AAT.
FT                                /FTId=PRO_0000364030.
FT   REGION      368    392       RCL.
FT   SITE        382    383       Reactive bond.
FT   MOD_RES      38     38       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     256    256       S-cysteinyl cysteine.
FT   MOD_RES     383    383       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    107    107       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:22171320}.
FT   VAR_SEQ     307    418       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_028890.
FT   VAR_SEQ     356    418       AVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
FT                                LMIEQNTKSPLFMGKVVNPTQK -> VRSP (in
FT                                isoform 2). {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_028889.
FT   VARIANT       4      4       S -> L (in Z-Wrexham).
FT                                {ECO:0000269|PubMed:2227940}.
FT                                /FTId=VAR_006978.
FT   VARIANT      26     26       D -> A (in V-Munich; dbSNP:rs199422212).
FT                                {ECO:0000269|PubMed:2316526}.
FT                                /FTId=VAR_006979.
FT   VARIANT      37     37       T -> A (in dbSNP:rs11558262).
FT                                /FTId=VAR_051938.
FT   VARIANT      58     58       A -> T (in M5-Karlsruhe;
FT                                dbSNP:rs149319176).
FT                                /FTId=VAR_006980.
FT   VARIANT      63     63       R -> C (in I; dbSNP:rs28931570).
FT                                {ECO:0000269|PubMed:2606478}.
FT                                /FTId=VAR_006981.
FT   VARIANT      65     65       L -> P (in M-Procida; dbSNP:rs28931569).
FT                                {ECO:0000269|PubMed:3262617}.
FT                                /FTId=VAR_006982.
FT   VARIANT      69     69       S -> F (in M6-Bonn; dbSNP:rs199687431).
FT                                /FTId=VAR_006983.
FT   VARIANT      75     75       Missing (in M-Malton, M-Nichinan and M-
FT                                Palermo; associated with very low serum
FT                                levels of AAT; homozygosity for allele M-
FT                                Malton may be associated with a risk for
FT                                chronic emphysema or infantile liver
FT                                cirrhosis). {ECO:0000269|PubMed:2309708,
FT                                ECO:0000269|PubMed:2606478,
FT                                ECO:0000269|PubMed:2786335}.
FT                                /FTId=VAR_006984.
FT   VARIANT      77     77       S -> F (in S-Iiyama; dbSNP:rs55819880).
FT                                {ECO:0000269|PubMed:1905728}.
FT                                /FTId=VAR_006985.
FT   VARIANT      84     84       A -> T (in M6-Passau; dbSNP:rs111850950).
FT                                /FTId=VAR_006986.
FT   VARIANT      91     91       G -> E (in M-Mineral springs; causes
FT                                reduced AAT secretion; dbSNP:rs28931568).
FT                                {ECO:0000269|PubMed:1967187}.
FT                                /FTId=VAR_006987.
FT   VARIANT      92     92       T -> I (in QO-Lisbon; deficient AAT with
FT                                very low serum levels).
FT                                /FTId=VAR_006988.
FT   VARIANT     109    109       T -> M (in Z-Bristol; deficient AA;
FT                                disrupts the N-glycosylation site N-107;
FT                                dbSNP:rs199422213).
FT                                {ECO:0000269|PubMed:9459000}.
FT                                /FTId=VAR_011620.
FT   VARIANT     112    112       P -> T (in M5-Berlin).
FT                                /FTId=VAR_006989.
FT   VARIANT     116    116       I -> N (in QO-Ludwigshafen;
FT                                dbSNP:rs28931572).
FT                                {ECO:0000269|PubMed:2254451}.
FT                                /FTId=VAR_006990.
FT   VARIANT     125    125       R -> H (in M2; associated with D-400;
FT                                dbSNP:rs709932).
FT                                /FTId=VAR_006991.
FT   VARIANT     139    139       G -> S (in QO-Newport; dbSNP:rs11558261).
FT                                {ECO:0000269|PubMed:2227940}.
FT                                /FTId=VAR_006992.
FT   VARIANT     172    172       G -> R (in V and M-Nichinan;
FT                                dbSNP:rs112030253).
FT                                /FTId=VAR_006993.
FT   VARIANT     172    172       G -> W (in M2-Obernburg;
FT                                dbSNP:rs112030253). {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_006994.
FT   VARIANT     180    180       Q -> E (in L-Frankfurt).
FT                                /FTId=VAR_006995.
FT   VARIANT     190    198       QGKIVDLVK -> GFQNAILVR (in Aberrant
FT                                form).
FT                                /FTId=VAR_036746.
FT   VARIANT     228    228       E -> K (in X; dbSNP:rs199422208).
FT                                /FTId=VAR_006996.
FT   VARIANT     237    237       V -> A (in M1A and Z; associated with K-
FT                                366 in Z; dbSNP:rs6647).
FT                                {ECO:0000269|PubMed:17650587,
FT                                ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.12, ECO:0000269|Ref.8}.
FT                                /FTId=VAR_006997.
FT   VARIANT     247    247       R -> C (in F; dbSNP:rs28929470).
FT                                {ECO:0000269|PubMed:2035534}.
FT                                /FTId=VAR_006998.
FT   VARIANT     280    280       D -> V (in P-Duarte/P-Cardiff/P-Lowell;
FT                                associated with H-415 in Y-Barcelona;
FT                                dbSNP:rs28929472).
FT                                {ECO:0000269|PubMed:10651487,
FT                                ECO:0000269|PubMed:2606478,
FT                                ECO:0000269|PubMed:8364590}.
FT                                /FTId=VAR_006999.
FT   VARIANT     288    288       E -> V (in S and T; dbSNP:rs17580).
FT                                {ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.17}.
FT                                /FTId=VAR_007000.
FT   VARIANT     305    305       Missing (in Basque).
FT                                {ECO:0000269|PubMed:10612848}.
FT                                /FTId=VAR_009216.
FT   VARIANT     354    354       S -> F (in S-Munich; dbSNP:rs201788603).
FT                                /FTId=VAR_007001.
FT   VARIANT     360    360       A -> T (in W-Bethesda; dbSNP:rs1802959).
FT                                {ECO:0000269|PubMed:2390072}.
FT                                /FTId=VAR_007002.
FT   VARIANT     365    365       D -> N (in P-St.Albans/P-Donauwoerth;
FT                                dbSNP:rs143370956).
FT                                /FTId=VAR_007003.
FT   VARIANT     366    366       E -> K (in Z/Z-Augsburg/Z-Tun; associated
FT                                with A-237 in Z; dbSNP:rs28929474).
FT                                {ECO:0000269|PubMed:2339709,
FT                                ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_007004.
FT   VARIANT     382    382       M -> R (in Pittsburgh; has antithrombin
FT                                activity; inhibits factor VIIa activity;
FT                                causes fatal bleeding diathesis;
FT                                dbSNP:rs121912713).
FT                                {ECO:0000269|PubMed:12860985,
FT                                ECO:0000269|PubMed:26797521}.
FT                                /FTId=VAR_007005.
FT   VARIANT     386    386       P -> H (in Sao Tome).
FT                                {ECO:0000269|Ref.73}.
FT                                /FTId=VAR_007006.
FT   VARIANT     386    386       P -> T (in L-Offenbach; dbSNP:rs12233).
FT                                /FTId=VAR_007007.
FT   VARIANT     387    387       E -> K (in Christchurch;
FT                                dbSNP:rs121912712).
FT                                /FTId=VAR_007008.
FT   VARIANT     393    393       P -> L (in M-Heerlen; dbSNP:rs199422209).
FT                                {ECO:0000269|PubMed:2784123}.
FT                                /FTId=VAR_007009.
FT   VARIANT     400    400       E -> D (in M2 and M3; associated with H-
FT                                125 in M2; dbSNP:rs1303).
FT                                {ECO:0000269|PubMed:17650587,
FT                                ECO:0000269|PubMed:2394452}.
FT                                /FTId=VAR_007010.
FT   VARIANT     415    415       P -> H (in Y-Barcelona; associated with
FT                                V-280). {ECO:0000269|PubMed:10651487}.
FT                                /FTId=VAR_007011.
FT   MUTAGEN     382    382       M->V: Oxidation-resistant inhibitor of
FT                                therapeutic importance.
FT                                {ECO:0000269|PubMed:6387509}.
FT   CONFLICT     12     12       Missing (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT     23     23       L -> P (in Ref. 11; BAG38005).
FT                                {ECO:0000305}.
FT   CONFLICT     26     26       D -> H (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     39     39       H -> L (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     61     61       L -> P (in Ref. 9; AAF29581).
FT                                {ECO:0000305}.
FT   CONFLICT     96     96       T -> A (in Ref. 7; ABG73380).
FT                                {ECO:0000305}.
FT   CONFLICT    139    140       GN -> DG (in Ref. 1; AAB59375).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       T -> H (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       E -> D (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT    273    273       T -> N (in Ref. 1; AAB59375).
FT                                {ECO:0000305}.
FT   CONFLICT    280    280       D -> G (in Ref. 7; ABG73380).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       V -> I (in Ref. 3; CAA25838).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       G -> L (in Ref. 24; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    414    414       N -> S (in Ref. 24; AA sequence).
FT                                {ECO:0000305}.
FT   TURN         48     50       {ECO:0000244|PDB:1HP7}.
FT   HELIX        51     68       {ECO:0000244|PDB:3NDD}.
FT   STRAND       70     72       {ECO:0000244|PDB:3NE4}.
FT   STRAND       74     76       {ECO:0000244|PDB:3NDD}.
FT   HELIX        78     89       {ECO:0000244|PDB:3NDD}.
FT   HELIX        94    103       {ECO:0000244|PDB:3NDD}.
FT   TURN        108    110       {ECO:0000244|PDB:3NDD}.
FT   HELIX       113    127       {ECO:0000244|PDB:3NDD}.
FT   STRAND      135    145       {ECO:0000244|PDB:3NDD}.
FT   STRAND      146    148       {ECO:0000244|PDB:1ATU}.
FT   HELIX       152    162       {ECO:0000244|PDB:3NDD}.
FT   STRAND      164    169       {ECO:0000244|PDB:3NDD}.
FT   STRAND      171    173       {ECO:0000244|PDB:1ATU}.
FT   HELIX       174    188       {ECO:0000244|PDB:3NDD}.
FT   TURN        189    191       {ECO:0000244|PDB:3NDD}.
FT   STRAND      206    220       {ECO:0000244|PDB:3NDD}.
FT   HELIX       224    226       {ECO:0000244|PDB:3NDD}.
FT   STRAND      228    235       {ECO:0000244|PDB:3NDD}.
FT   STRAND      238    256       {ECO:0000244|PDB:3NDD}.
FT   TURN        257    260       {ECO:0000244|PDB:3NDD}.
FT   STRAND      261    279       {ECO:0000244|PDB:3NDD}.
FT   STRAND      280    282       {ECO:0000244|PDB:1ATU}.
FT   HELIX       284    290       {ECO:0000244|PDB:3NDD}.
FT   HELIX       293    301       {ECO:0000244|PDB:3NDD}.
FT   STRAND      306    313       {ECO:0000244|PDB:3NDD}.
FT   STRAND      315    322       {ECO:0000244|PDB:3NDD}.
FT   HELIX       324    329       {ECO:0000244|PDB:3NDD}.
FT   HELIX       334    336       {ECO:0000244|PDB:3NDD}.
FT   TURN        337    339       {ECO:0000244|PDB:1QMB}.
FT   TURN        343    345       {ECO:0000244|PDB:3NDD}.
FT   STRAND      347    349       {ECO:0000244|PDB:3NDD}.
FT   STRAND      351    364       {ECO:0000244|PDB:3NDD}.
FT   STRAND      366    381       {ECO:0000244|PDB:3NDD}.
FT   STRAND      387    389       {ECO:0000244|PDB:3NDD}.
FT   STRAND      394    400       {ECO:0000244|PDB:3NDD}.
FT   TURN        401    403       {ECO:0000244|PDB:3NDD}.
FT   STRAND      406    414       {ECO:0000244|PDB:3NDD}.
SQ   SEQUENCE   418 AA;  46737 MW;  7016555F273B7F16 CRC64;
     MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS
     LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF
     QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ
     INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV
     KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL
     ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA
     VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK
//
